Vascular Biogenics Ltd VBLT shares are trading higher by $3.28 at $7.25 in Monday's session. After the close on Friday, the company reported data that showed significant overall survivor benefit in rGBM patients receiving VB-111 versus historical Avastin.
That news accounted for the higher open from Friday's close of $3.97 to $5.82. After a brief retreat to $5.52, it resumed its move higher.
Around 10:00 a.m. ET, rumors surfaced the company may be a takeover candidate for Bristol Myers Squibb BMY. That accounted for sprint to new highs at $7.36. That marks the highest level for the issue since it peaked on October 23 at $7.47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
